What Abacus International does

Abacus International is a privately held UK-based health economics and market access consultancy headquartered in Bicester. Founded in 1995, the firm is positioned in the health economics and outcomes research (HEOR) value chain, delivering services to pharmaceutical and biotechnology companies that require payer-grade evidence for reimbursement, access, and regulatory decisions. Its offerings span four tightly related disciplines: health outcomes research, economic modelling (cost-effectiveness, budget impact, and disease modelling), health technology assessment (HTA) submissions for bodies such as NICE, IQWiG, HAS, CADTH and others, and medical writing for publications and regulatory dossiers, with an accompanying market access advisory layer.

Operationally the firm runs a project-based professional services model, with revenue mechanics tied to defined deliverables (models, dossiers, manuscripts, value communications) typically scoped against client product launch or access milestones. The headcount band of 101-250 employees places it in the small-to-mid tier of the specialist HEOR consultancy market, well below global evidence-services platforms (Evidera, Parexel, IQVIA real-world evidence) but comparable to peer UK and European boutique HEOR/HTA firms. The customer base is concentrated in pharmaceutical and biotech manufacturers, particularly those needing support navigating evidence requirements across multiple payer jurisdictions.

As a niche specialist, Abacus International's competitive position depends on the depth of its methodologies, the credibility of its HTA submissions, and the long-tenured relationships it maintains with pharma access teams and HTA agencies. The firm has operated continuously for nearly three decades without a public listing or scale-disrupting M&A visible in the supplied data, suggesting a stable, relationship-driven operator rather than a venture-backed growth platform. Strategic posture going forward will be shaped by consolidation pressure in the HEOR services market, the increasing use of AI/automation in evidence synthesis, and the demand from sponsors for global, multi-payer evidence packages.

Name

Abacus International

Website

https://abacusint.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Abacus International is a UK-based health economics and market access consultancy founded in 1995 that delivers health outcomes research, economic modelling, health technology assessment submissions, medical writing, and market access services to pharmaceutical and biotechnology clients across multiple payer jurisdictions.

Ownership category

akta.pro rank

Product category

Health Economics and Outcomes Research (HEOR) Services

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

Keywords

• Health economics consulting
• Health technology assessment
• Market access services
• Medical writing services
• Health outcomes research

Headquarters

HQ city

Bicester

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Core offering

Abacus International is a UK-based health economics and market access consultancy that delivers health outcomes research, economic modelling, Health Technology Assessment (HTA), medical writing, and market access services. The firm supports pharmaceutical and biotech clients with evidence-based analyses and strategic communications to facilitate product development, reimbursement, and market entry. Founded in 1995 and headquartered in Bicester, United Kingdom, Abacus International operates as a privately held for-profit services provider with 101-250 employees.

Product overview

Clarivate (formerly Decision Resources Group) offers a comprehensive AI-powered intelligence platform for the life sciences and healthcare industry. The portfolio centers on the Cortellis platform, which provides competitive intelligence, product intelligence, deals intelligence, drug discovery intelligence, clinical trials intelligence, and regulatory intelligence across the pharmaceutical and biotech lifecycle. Supporting products include DRG Market Assessment and Epidemiology Intelligence for disease analytics, BioWorld for industry news, OFF-X for translational safety, and various consulting services. The platform is designed for portfolio strategy, R&D, commercialization, manufacturing/supply chain, and Medtech companies, offering both integrated intelligence modules and APIs for data integration.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Outcomes Research Research services focused on health outcomes evidence generation to support pharmaceutical and biotech clients in demonstrating real-world and clinical value of therapies.
• Economic Modelling Development of health economic models to support pricing, reimbursement, and payer decision-making for pharmaceutical products.
• Health Technology Assessment (HTA) HTA services supporting payer submissions and reimbursement evaluations for therapies across relevant jurisdictions.
• Medical Writing Scientific and medical writing services for pharmaceutical and biotech clients, including manuscripts, reports, and regulatory/scientific communications.
• Market Access Services Strategic market access support for pharmaceutical and biotech clients, including payer engagement, value communication, and reimbursement strategy.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Recent moves2 records

Expansion highlights2 records

Direct peers

• Analysis Group: Analysis Group runs a large Health Economics and Outcomes Research practice providing health economic modelling, real-world evidence, and value communications for pharma — a recognized competitor in HEOR and market access advisory.
• BresMed: BresMed is a UK-based HEOR and market access consultancy providing health economic modelling, systematic reviews, and HTA submissions — a niche direct competitor with comparable geographic and service-line footprint to Abacus.
• Evidera (PPD/Thermo Fisher Scientific): Evidera is the largest dedicated HEOR, real-world evidence, and market access consultancy, serving the same pharma/biotech buyer with health economic modelling, HTA submissions, and value communications — a direct head-to-head competitor for Abacus's core service lines.
• Cytel: Cytel provides biostatistics, HEOR, and real-world evidence consulting and software for pharma and medical device companies — a specialist competitor with strong overlap in economic modelling and clinical evidence work.
• RTI Health Solutions: RTI Health Solutions is a dedicated HEOR, patient-centered outcomes, and market access consultancy serving the same pharma/biotech client base with health economic modelling and HTA evidence generation comparable to Abacus's services.
• Clarivate (formerly Decision Resources Group): Clarivate's DRG/Market Access Intelligence division provides competitive and market access intelligence, disease epidemiology, and HEOR-adjacent analytics for pharma — the broadest direct overlap with Abacus's HTA and market access offerings, evidenced in the source data by its DRG Market Assessment, Market Access Intelligence, and Healthcare Business Insights modules.

Broad incumbents

• Parexel International: Parexel's market access, HEOR, and medical communications practices directly overlap with Abacus's HTA, health economic modelling, and medical writing services, serving the same pharma/biotech client base across launch readiness.
• ICON plc: ICON is a leading global CRO whose commercial and consulting services (post-PRA Health Sciences, post-Symphony Health) include HEOR, market access, and real-world evidence work that competes for the same pharma launch and evidence-generation budgets as Abacus.
• IQVIA: IQVIA is a global pharma services incumbent with substantial HEOR, real-world evidence, and market access capabilities operating across the full drug development lifecycle; Abacus competes against the same pharma buyers for HTA and evidence-generation budgets, but as a specialist against IQVIA's much broader portfolio.

Regional players

• PHARMO Institute (IQVIA): PHARMO is a Netherlands-based health outcomes and real-world evidence research organization (now part of IQVIA) providing population-based outcomes research for European pharma — comparable to Abacus's European market access and real-world evidence work.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/abacusint
• Facebookfacebook.com/decisionresourcesgroup
• LinkedInlinkedin.com/company/abacus-international_2
• Instagraminstagram.com/lifeatclarivate

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abacus International